Skip to content

Efficacy and safety of an innovative topical product(ß-glucan and peptide) combined 1565nm nonablative fractional laser in the treatment of striae gravidarum: a single-center randomized control trial

Efficacy and safety of an innovative topical product(ß-glucan and peptide) combined 1565nm nonablative fractional laser in the treatment of striae gravidarum: a single-center randomized control trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900021997
Enrollment
Unknown
Registered
2019-03-19
Start date
2018-05-31
Completion date
Unknown
Last updated
2019-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Striae Gravidarum

Interventions

B:topical vehicle
A:topical product (ß-glucan and polypeptide)
C:topical product(ß-glucan and polypeptide) combined 1565nm nonablative fractional laser
D:topical vehicle combined nonabative fractional laser

Sponsors

Shanghai Skin Disease Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 44 Years

Inclusion criteria

Inclusion criteria: 1. Aged over 18,who has abdominal striae gravidarum,both striae alba and striae rubra are included; 2. Fizpatrick III-IV type,two sides of the striae are general symmetric; 3. Agree to paticipate in the clinical trial and are able to follow up,sign the Inform Consent Form.

Exclusion criteria

Exclusion criteria: 1. Be pregnant or prepare for pregnancy; 2. Scar diathesis(who has a history of keloid); 3. There are active skin diseases on the skin of abdomen; 4. Have a history of laser treatment or other kinds of treatment which are able to affect the study within half year; 5. Accept oral corticosteroid or other immunosuppressors; 6. Have systemic diseases like coagulation disorders,psychological disorders,infectious diseases; 7. Allergic to any known ingredients or procaine/lidocaine.

Design outcomes

Primary

MeasureTime frame
width of striae gravidarum;

Secondary

MeasureTime frame
concavation of striae gravidarum;improvement validity;the color of striae gravidarum;The barrier function of the striae gravidarum;

Countries

China

Contacts

Public ContactPeiru Wang

Shanghai Skin Disease Hospital

wpeiru@qq.com+86 18017336579

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026